<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03087110</url>
  </required_header>
  <id_info>
    <org_study_id>HREC/14/RCHM/38; RCH ID 34210</org_study_id>
    <secondary_id>U1111-1179-9253</secondary_id>
    <nct_id>NCT03087110</nct_id>
  </id_info>
  <brief_title>Stem Cells in Umbilical Blood Infusion for CP</brief_title>
  <acronym>SCUBI-CP</acronym>
  <official_title>Safety Study of Sibling Cord Blood Cell Infusion to Children With Cerebral Palsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Murdoch Childrens Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Royal Children's Hospital Melbourne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Health Queensland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Monash Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sydney Children's Hospitals Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cerebral Palsy Alliance</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Murdoch Childrens Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the safety of single dose intravenous infusion of cord blood
      cells which were cryopreserved after the birth of a brother or sister to a child with
      cerebral palsy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cerebral palsy (CP) is the most common physical disability of childhood, affecting 2 per 1000
      live births across the world. CP describes permanent non-progressive motor disorders arising
      from damage to the developing brain.

      Preclinical studies of different types of stem cells in models of acute brain injury similar
      to CP have shown significant functional improvement. The variety of stem cells available in
      umbilical cord blood (UCB), an ethically uncomplicated source of stem cells, has led to a
      focus on UCB stem cell therapy as a quick-to-clinic option. Previous studies indicate that
      autologous or unrelated donor UCBC infusion is safe and feasible for children with CP, and
      may lead to improved motor functioning, but there is no information about the safety and
      effects of matched sibling cord blood. Therefore, this trial will study the safety of
      infusing matched sibling cord blood cells to children with cerebral palsy.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with abnormal clinical assessment and/or laboratory values</measure>
    <time_frame>12 months</time_frame>
    <description>Safety</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preliminary analysis of change in gross motor function</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Gross Motor Function Measure (GMFM-66)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary analysis of change in gross motor function</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Gross Motor Function Measure (GMFM-66)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary analysis of change in fine motor function</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Quality of Upper Extremity Skills Test (QUEST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary analysis of change in fine motor function</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Quality of Upper Extremity Skills Test (QUEST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary analysis of change in cognitive function</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Age appropriate cognitive testing: Bayley Scales of Infant and Toddler Development (BSID-III), Wechsler Preschool Primary Scale of Intelligence (WPPSI-IV), Wechsler Intelligence Scale for Children (WISC-V). Change from baseline will be compared using z-scores across measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary analysis of change in quality of life</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Cerebral Palsy Quality of Life (CP-QoL-CHILD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary analysis of change in quality of life</measure>
    <time_frame>Baseline,12 months</time_frame>
    <description>Cerebral Palsy Quality of Life (CP-QoL-CHILD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digital PCR analysis of peripheral blood cellular DNA to determine the fraction of donor DNA in circulation</measure>
    <time_frame>3 months</time_frame>
    <description>Chimerism study to detect the longevity of infused cells</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Cerebral Palsy</condition>
  <arm_group>
    <arm_group_label>Cord blood infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Matched sibling donor cord blood cell infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Matched sibling donor cord blood cell infusion</intervention_name>
    <description>Single dose intravenous infusion of 12/12 HLA matched sibling donor cord blood cells (&gt;1x10^7 cells/kg)</description>
    <arm_group_label>Cord blood infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of any type of CP

          2. CP of any severity

          3. A record of sibling CBU in storage at a TGA accredited private cord blood bank

          4. Ability to travel to one of the trial centres

          5. Ability to participate in assessments

          6. Informed consent by parent/guardian

        Exclusion Criteria:

          1. presence of progressive neurological disease

          2. known genetic disorder

          3. known brain dysplasia

          4. immune system disorder or immune deficiency syndrome

          5. infectious disease markers showing up on virology screen

          6. evidence of cord blood unit contamination, or fewer than 10^7 cells/kg body mass

          7. ventilator support

          8. ill health, or if the participant's medical condition does not allow safe travel

          9. previous cell therapy

         10. Botulinum toxin A within 3 months before or after infusion

         11. surgery within 3 months before or after infusion

         12. cannot obtain parent/guardian consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dinah Reddihough, MBChB, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Group leader</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lady Cilento Children's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Children's Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2017</study_first_submitted>
  <study_first_submitted_qc>March 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2017</study_first_posted>
  <last_update_submitted>July 4, 2017</last_update_submitted>
  <last_update_submitted_qc>July 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Palsy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

